Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer

Published Date: 25 Sep 2025

Molecular profiling has transformed cancer care, but 30% of high-risk pediatric cancers do not have actionable therapeutic targets, limiting personalized treatment options and negatively affecting survival outcomes.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.

2.

A Win for Molecularly Guided Therapy for Cancer of Unknown Primary

3.

Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds

4.

FDA Authorizes Three Different Uses for Injectable Antibiotic.

5.

Five new papers highlight cancer inequities, challenges and opportunities in South Asia


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot